These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 17307059)

  • 1. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
    Lee M; Aronne LJ
    Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and strategies in managing cardiometabolic risk.
    Repas TB
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S4-11. PubMed ID: 17784529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifestyle modification and endothelial function in obese subjects.
    Hamdy O
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):231-41. PubMed ID: 15853597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of diabetes in patients with severe obesity.
    Scheen AJ
    Biomed Pharmacother; 2000 Mar; 54(2):74-9. PubMed ID: 10759290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease.
    Després JP
    J Endocrinol Invest; 2006; 29(3 Suppl):77-82. PubMed ID: 16751711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet needs in controlling metabolic disease.
    Haffner SM
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
    Haffner SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes?
    Joffe D; Yanagisawa RT
    Med Clin North Am; 2007 Nov; 91(6):1107-23, ix. PubMed ID: 17964912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
    Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.